Abstract Number: 379 • 2012 ACR/ARHP Annual Meeting
Persistency and Predictors of Persistency of Adalimumab Among Rheumatoid Arthritis (RA) Patients in a US Registry
Background/Purpose: There are limited observational data to guide physician decision-making when choosing to begin a patient on a new biologic treatment. Understanding real-world trends in…Abstract Number: 380 • 2012 ACR/ARHP Annual Meeting
DMARD and Biologic Use During Pregnancy Among Rheumatoid and Psoriatic Arthritis Patients in the Corrona Registry
Background/Purpose: CORRONA is a nationwide longitudinal disease-based registry that includes 32875 rheumatoid (RA) and 5462 psoriatic arthritis (PsA) patients. We sought to ascertain the frequency…Abstract Number: 381 • 2012 ACR/ARHP Annual Meeting
DAS Does Not Predict Increasing Treatment in Early Rheumatoid Arthritis: Results From the CATCH Study
Background/Purpose: The disease activity score (DAS) was developed in RA to guide therapy. Its utility in practice for early rheumatoid arthritis (ERA) has not been…Abstract Number: 382 • 2012 ACR/ARHP Annual Meeting
Does Biased Risk Perception Explain the Underuse of Disease Modifying Anti-Rheumatic Drugs?
Background/Purpose: The prescription of a Disease Modifying Anti-rheumatic Drugs (DMARD) for patients with rheumatoid arthritis (RA) is considered a standard of effective care. However a…Abstract Number: 383 • 2012 ACR/ARHP Annual Meeting
2002-04 Vs.2007-09: Initiation of Combination, and Tapering/Discontinuation (DC) Patterns of TNFi and MTX in a US (RA) Patient Registry: Analysis with CDAI Scores
Background/Purpose: We compared patient (pt) characteristics, for initiating, tapering and DC of TNFi/MTX combination therapy (CT), among RA pts seen during 02-04 vs. 07-09 to…Abstract Number: 384 • 2012 ACR/ARHP Annual Meeting
Treating Rheumatoid Arthritis to Target: A Canadian Patient Survey
Background/Purpose: Recently, many countries, including Canada, evaluated rheumatologists’ acceptance and agreement with a set of 10 Treat to Target (T2T) recommendations for rheumatoid arthritis (RA),…Abstract Number: 385 • 2012 ACR/ARHP Annual Meeting
The Wide Variation in Corticosteroid Use in Early Rheumatoid Arthritis – There Is Need for Guidelines
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease which causes significant pain and swelling in the joints. The early treatment of the disease mainly…Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting
Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…Abstract Number: 387 • 2012 ACR/ARHP Annual Meeting
Medication Choices and Medication Survival in a National Multicentre Community Based Rheumatoid Arthritis Cohort
Background/Purpose: A sizeable body of high-quality research underpins our knowledge of the efficacy of various RA therapies. Outside the controlled environment of these clinical trials,…Abstract Number: 388 • 2012 ACR/ARHP Annual Meeting
Retention Rate of the Anti-TNF Biologics in the Treatment of Rheumatic Diseases and Predictive Factors for Drug Withdrawal: Data From the Hong Kong Biologics Registry
Background/Purpose: To study the retention rate of the anti-TNF biologics in the treatment of rheumatic diseases and the associated factors for drug withdrawal Methods: Data…Abstract Number: 389 • 2012 ACR/ARHP Annual Meeting
Oral Glucocorticoid Sparing Effects of Rituximab in Rheumatoid Arthritis Patients Who Have Switched from an Anti-TNF Therapy – an Administrative Claims Database Analysis
Background/Purpose: The current treatment paradigm in RA is to attempt to decrease concomitant use of oral glucocorticoids (OGC). This study examined the OGC-sparing effects of…Abstract Number: 350 • 2012 ACR/ARHP Annual Meeting
Reduction of Inflammation with Abatacept and Tocilizumab Results in Lower N-Terminal Pro Brain Natriuretic Peptide Levels in Patients with Rheumatoid Arthritis: Results From Prospective Cohort Studies
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of heart failure (HF). The chronic inflammatory state in RA is associated with increased levels of…Abstract Number: 351 • 2012 ACR/ARHP Annual Meeting
Prospective Follow-up of Tocilizumab Treatment in 764 Patients with Refractory Rheumatoid Arthritis: Tolerance and Efficacy Data From the French Registry Regate (REGistry –RoAcTEmra)
Background/Purpose: To assess tolerance and safety of rheumatoid arthritis (RA) treatment by tocilizumab (TCZ) in real life Methods: The French Society of Rheumatology and the…Abstract Number: 352 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis
Background/Purpose: Vaccines against influenza and streptococcus pneumonia are currently recommended for patients with rheumatoid arthritis (RA). This meta-analysis assesses current literature data on the impact…Abstract Number: 353 • 2012 ACR/ARHP Annual Meeting
The Effect of Combination Therapy and Prednisolone On Haemostatic Markers in Rheumatoid Arthritis
Background/Purpose: There is accumulating evidence that rheumatoid arthritis (RA) should be considered as prothrombotic state, explaining the increased risk of thromboembolic events. Suppressing inflammation could…